Venetoclax + Azacitidine + Azacitidine
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Mar 26, 2020 → Jun 1, 2026
NCT ID
NCT04102020About Venetoclax + Azacitidine + Azacitidine
Venetoclax + Azacitidine + Azacitidine is a phase 3 stage product being developed by AbbVie for Acute Myeloid Leukemia (AML). The current trial status is active. This product is registered under clinical trial identifier NCT04102020. Target conditions include Acute Myeloid Leukemia (AML).
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07044687 | Approved | Recruiting |
| NCT04102020 | Phase 3 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)